INTRODUCTION
Late-life depression (LLD) is associated with significant negative outcomes, including disability and greater all-cause mortality (Taylor, 2014) . Antidepressant medications may be helpful but are less effective in older populations (Taylor & Doraiswamy, 2014; Tedeschini et al., 2004) and LLD is associated with a high risk of recurrence. Community studies examining LLD report that 19-34% recover, 27-32% remain chronically ill, and approximately 40% experience a fluctuating course (Beekman et al., 2002) . However, key clinical, environmental, and neurobiological factors that influence recurrence are poorly understood.
Although few studies of recurrence focus on LLD, existing research largely examined clinical factors. Recurrence is most consistently associated with residual symptoms (Judd et al., 1998; Nierenberg et al., 2010) and number of prior depressive episodes, while depression severity and age of initial depression onset are inconsistently reported (Alexopoulos et al., 2000; Alexopoulos, Young, Abrams, Meyers, & Shamoian, 1989; Hinrichsen & Hernandez 1993; Stoudemire, 1997) . Demographic differences are not related to recurrence, other than female sex that is associated with recurrence in midlife (Gueorguieva, Chekroud, & Krystal, 2017; Mueller et al., et al., 2000; Hinrichsen & Hernandez 1993; Solomon et al., 2004) .
Comorbid psychiatric symptoms, including sleep and anxiety symptoms predict recurrence (Andreescu et al., 2007; Reynolds et al., 2006) , but not medical comorbidity or disability (Alexopoulos et al., 1989 (Alexopoulos et al., , 2000 Hinrichsen & Hernandez 1993; Reynolds et al., 2006) .
Environmental influences are anecdotally related to recurrence, but published data are mixed. Positive social supports including marriage may reduce recurrence risk but this is not consistently supported (Burcusa & Iacono 2007; Hinrichsen & Hernandez 1993; Kuehner & Huffziger 2013; Mueller et al., 1999; Patten et al., 2010; Solomon et al., 2004; van Loo, Aggen, Gardner, & Kendler, 2015) .
Similarly, negative stressful life events including lower socioeconomic status are not consistently associated with recurrence (Alexopoulos et al., 1989; Burcusa & Iacono 2007; Hinrichsen & Hernandez 1993; Patten et al., 2010; Solomon et al., 2004; van Loo et al., 2015) .
Few studies used neurocognitive or neuroimaging assessments to examine recurrence. Although poor cognitive performance is common in LLD and associated with poor antidepressant response , the effects on recurrence are unclear. Although some did not associate recurrence with cognitive impairment (Butters et al., 2004) , others identify executive dysfunction but not memory impairment as a risk factor (Alexopoulos et al., 2000) . Using neuroimaging, hippocampal atrophy in the elderly is associated with greater and persistent depression severity (Buddeke et al., 2016; Taylor et al., 2014) . Greater change in white matter hyperintensity (WMH) volumes, a marker of vascular risk, is also associated with poorer longer term depression outcomes (Taylor et al., 2003) .
These data do not provide a clear picture of the factors most predictive of depression recurrence in remitted LLD. Existent reports often focus on specific clinical features and do not provide a holistic picture.
The purpose of this study was to examine a wide range of clinical, environmental, medical, cognitive, and imaging measures in the longitudinal neurocognitive outcomes of depression in the elderly (NCODE) cohort in order to determine what factors best predict recurrence in LLD. We hypothesized that, in conjunction with other measures, residual depressive symptoms, female sex, and stress exposure would predict recurrence.
METHODS

Participants
NCODE methods have previously been described (Steffens et al., 2004) . The NCODE study enrolled participants from 1995 to 2006 at Duke University Medical Center. Eligible subjects were of age 60 years or older with a DSM-IV diagnosis of major depressive disorder and a Center for Epidemiologic Studies-Depression (CES-D) score > 15. Exclusion criteria included: (1) another major psychiatric illness, although comorbid anxiety was allowed; (2) current or past alcohol or drug dependence; (3) primary neurologic illness, including dementia; (4) Mini-Mental State Examination (MMSE) score < 25; (5) physical disability precluding cognitive testing; and (6) for magnetic resonance imaging (MRI), any specific MRI contraindications.
This study included a treatment as detailed below and only subjects who achieved remission during their study participation were included in analyses.
The study was approved by the Duke University Institutional review board. All participants provided written informed consent.
Clinical assessments and treatment
A trained interviewer administering the Duke Depression Evaluation Schedule (DDES) (Landerman, George, Campbell, & Blazer, 1989 ) assessed for depression using the National Institute of Mental Health (NIMH) Diagnostic Interview Schedule. The DDES also assessed for comorbid generalized anxiety disorder (GAD) per DSM-IV criteria. A study geriatric psychiatrist confirmed diagnoses based on clinical interview and other instruments, including the Montgomery-Asberg Depression Rating Scale (MADRS) (Montgomery & Asberg 1979) .
The NCODE study operated in a naturalistic milieu where subjects were treated according to the Duke Somatic Treatment Algorithm for Geriatric Depression (Steffens, McQuoid, & Krishnan, 2002 ) (Supporting information). For participants who achieve remission, the protocol recommends continued treatment for at least 1-2 years, if not indefinitely. Participants were seen at least every 3 months, medication use documented, and MADRS administered. Psychotropic medication use was categorized into drug classes, including antidepressants, anxiolytics, sedative/hypnotics, and antipsychotics, including lithium.
When available, antidepressant dose at censoring was calculated using fluoxetine dose equivalents (Supporting information) (Hayasaka et al., 2015) .
Demographic, environmental, and medical assessments
The DDES interview acquired demographic information, age of initial depression onset, and number of prior depressive episodes. Using our prior approach (Burke et al., 2011; Riddle et al., 2017) , we dichotomized the sample into early-onset depression (EOD, onset before the age of 50 years) and late-onset depression (LOD, onset at the age of 50 years or later). Guided by past recommendations (Nierenberg, Petersen, & Alpert, 2003) , we examined number of prior episodes as a continuous measure and by dichotomizing the sample by those who reported more than three prior episodes.
Assessments are detailed in the Supporting information. Medical illness was quantified using the Cumulative Illness Rating Scale (CIRS) (Miller et al., 1992) and disability by self-report of instrumental activities of daily living (IADL) (Steffens, Hays, & Krishnan, 1999) . Measurements of life stress assessed perceived stress severity (on a 10-point scale), the occurrence and valence of stressful events common in later life (negative, positive, or neutral) (Hays et al., 1997) , and participant ability to meet their financial needs. The Duke Social Support Index assessed social network size, frequency of interactions, social assistance with instrumental activities (instrumental social support), and subjective social support (Landerman et al., 1989 ).
Neuropsychological assessment
The neuropsychological test battery was previously described (Potter, McQuoid, & Steffens, 2015; Steffens et al., 2004) . As per our previous strategy (Potter et al., 2015; Riddle et al., 2017) , we created z-scores for each neuropsychological measure derived from performance across all participants so we could combine different neuropsychological tasks for a measure of overall cognitive domain performance. We created cognitive domain scores by averaging z-scores across tests, grouped into rational cognitive domain constructs of episodic memory, executive function, working memory, and verbal fluency (Supporting information). For these analyses, we examined z-transformed cognitive domain scores calculated from the entire NCODE sample (including depressed and never-depressed participants) and also examined domain z-scores calculated only from the sample included in this study (depressed participants who remitted).
Neuroimaging
Neuroimaging was initiated after the original study had started, so imaging data are not available for all participants. Subjects were imaged with a 1.5T whole-body MRI system (Signa, GE Medical Systems, Chicago, IL, USA) using the standard head (volumetric) radiofrequency coil. MRI was obtained at baseline or within the first 2 weeks; acquisition parameters and volumetric analyses have been previously described (Payne et al., 2002; Steffens et al., 2000) (Supporting information).
Statistical analyses
Statistical analyses were conducted using SAS 9.4 (Cary, NC, USA).
Initial univariate analyses tested for differences between individuals who did and did not experience recurrence. Remission was defined as a MADRS score of 7 or less and recurrence as a subsequent MADRS score of 15 or greater.
Survival analyses examined time to recurrence or censoring. This approach used Cox proportional hazards models (PROC PHREG in SAS) with a priori defined core covariates of age and sex, selected due to our focus on an older population and because depression is more common in women. Additional covariates were added as scientifically indicated, such as education for models assessing cognition and intracranial volume when assessing MRI variables. Using these covariates, most initial models examined single predictor variables. For analyses of individual items derived from the baseline depression scales, we first tested for group differences in individual item scores then incorporated items exhibiting a statistically significant group difference into a proportional hazard model predicting time to recurrence. Backward stepwise regression was then conducted to identify individual items predictive of recurrence.
A similar approach was used for the final analyses. Variables exhibiting a statistically significant relationship with time to recurrence in previous analyses at an = 0.05 were included in a final proportional hazards model. A final parsimonious model was developed using backwards regression, after that we calculated hazard ratios and 95% confidence intervals. As we intended to consider both total scores on depression scales and individual depression scale items, we planned for two competing models examining these different approaches. Our final results utilized the model with the best statistical fit per Akaike information criteria (AIC) and Schwarz Bayesian information criteria (SBC).
RESULTS
Of 412 total depressed elders, 171 (41.5%) did not achieve remission during study participation so were not included in analyses. Of the 241 elders who remitted, 137 (33.31% of the total sample, or 56.8% of the remitted sample) experienced recurrence of depression during subsequent study participation, while 104 did not (25.2% of the total sample, or 43.2% of the remitted sample). This remitted population was followed in the NCODE study for a mean period of 3.75 years (SD = 3.79 years).
Recurrent and nonrecurrent groups did not significantly differ in demographic characteristics (Table 1) , but differed in time followed after remission but before censoring ( Figure 1 ). Approximately 75% of those who experienced recurrence did so within 2 years of remission. In an initial model examining age, sex, race, education, and baseline depression severity by MADRS, no variables were significantly associated with recurrence. However, in a parsimonious model of a priori defined demographics, female sex (Wald 2 = 4.72, P = .0299) but not age (Wald 2 = 0.39, P = .5303) was associated with recurrence.
Clinical factors
We first focused on clinical factors related to depression (Table 1) .
In univariate analyses, time to remission did not significantly differ between recurrent and nonrecurrent groups. In contrast to the clinician-rated MADRS, the recurrent group exhibited higher baseline scores on the patient-rated CES-D; in models controlling for age and sex, total CES-D score was associated with recurrence risk (Wald 2 = 19.51, P < .0001). Individuals with recurrent depression also exhibited significantly higher MADRS scores in the evaluation prior to recurrence or censoring, although the mean difference between groups was only two points. In models controlling for age and sex, precensoring MADRS scores were associated with recurrence risk (Wald 2 = 16.34, P < .0001).
We next examined individual baseline CES-D and MADRS items. In univariate analyses, subjects exhibited higher scores on many CES-D items, but only in items of reported sadness and suicidal thoughts on the MADRS (Supporting information Tables S1 and S2 ). When incorporated into a model and after backwards regression, time to recurrence was associated only with CES-D item 18 (felt sad; Wald 2 = 13.30, P = .0003) and MADRS item 10 (suicidal thoughts; Wald 2 = 6.42,
The recurrent group also exhibited an earlier age at first depressive episode (Table 1) . When controlling for age and sex, an earlier age of initial depression onset was associated with recurrence risk Wald 2 = 6.45, P = .0111). Finally, comorbid GAD rates did not differ between recurrence groups and GAD did not predict recurrence risk (Wald 2 = 0.28, P = .5983).
Psychotropic medication use
We examined psychotropic medication use both at study entry and at time of censoring. After controlling for age and sex, psychotropic medication use (antidepressants, anxiolytics, sedative/hypnotics, or antipsychotics) at enrollment was not associated with recurrence risk (Supporting information Table S3 ). Similarly, psychotropic medication use at censoring was not associated with recurrence risk, aside from anxiolytic use that was associated with increased recurrence risk (recurrent, 32.9% (N = 45); nonrecurrent, 19.2% (N = 20); Wald 2 = 5.28, P = .216). The majority of study participants were taking an antidepressant medication at censoring (recurrent, 89.1% (N = 122); nonrecurrent, 83.7% (N = 87); 2 = 1.50, 1df, P = .2213).
Although not available for all participants, at censoring the recurrent group was taking a higher mean fluoxetine-equivalent antidepressant dose than the nonrecurrent group (recurrent, N = 122: 42.7 mg (29.5 mg); nonrecurrent, N = 75: 33.6 mg (20.6 mg); Satterthwaite t = 2.53, 191.86 df, P = .0122).
Medical and environmental factors 3.3.1 Medical
Greater IADL disability but not greater medical morbidity as measured by the CIRS was associated with recurrence risk (Table 2 ).
Stress
Aside from positively valenced stressful events, all stress measures were associated with recurrence (Table 2) . In adjusted models, the total number of stressful life events score was associated with recurrence, a finding primarily driven by negative stressful events. Similarly, higher perceived stress was associated with recurrence.
We next explored financial stress. We observed a discrepancy where there was no group difference in having enough money to meet their needs ( 2 = 0.09, 1df, P = .7653), but there was a difference in having difficulty making payments ( 2 = 5.42, 1df, P = .0199). In models, only difficulty with payments was associated with time to recurrence (Table 2) .
Social support
In adjusted models, lower levels of instrumental social support and less subjective social support were associated with risk of recurrence, but not with social network size or social interactions (Table 2) . We did not observe a relationship between current marital status and recurrence.
Neuropsychological test performance
The mean z-transformed cognitive test domain scores calculated from the entire NCODE sample were generally lower for recurrent than the nonrecurrent group. However, in adjusted models, no domain score was significantly associated with recurrence risk (Table 3) . Similarly, baseline MMSE score was not associated with recurrence risk. In secondary analyses, we recalculated z-scores based on only participants included in this analyses. Again, we did not find an association between domain scores and recurrence risk (data not shown).
Neuroimaging predictors
We examined the effects of baseline neuroimaging markers of brain aging on risk of recurrence in individuals with MRI data. There were no demographic differences between those with and without neuroimaging data. After adjusting for covariates, we did not associate recurrence risk with total cerebral volume, total gray matter, ventricular volume, hippocampus volume, or WMH volume (Table 3 ).
Composite models predicting time to recurrence
We incorporated the variables identified in the above analyses into composite models and conducted backwards regression to create final parsimonious models. We examined two competing models examin- (Table 4) .
Finally, we added the dichotomized number of prior depressive episodes variable to the parsimonious model, reducing the sample size to 182 participants (Table 4) . Having more than three prior episodes significantly predicted recurrence risk, while female sex, younger age of onset, and baseline MADRS item 10 no longer predicted recurrence.
DISCUSSION
Over a mean duration of approximately 4 years and despite most continuing antidepressant treatment, 56.8% of older adults with remitted depression experienced recurrence while 43.2% remained in remission. Approximately 75% of those who experienced recurrence did so within 2 years of remission. This replicates prior clinical and population studies (Alexopoulos et al., 1989 (Alexopoulos et al., , 2000 Beekman et al., 2002; Reynolds et al., 2006) All analyses examine 241 participants, except for analyses examining perceived stress and financial problems due to missing data. Results are presented for models controlling for age and sex. CIRS, Cumulative Illness Rating Scale severity index; IADL, instrumental activities of daily living.
Effects of demographic variables and clinical measures
Demographic factors associated with recurrence differ from past studies. We found that women were approximately 50% more likely than men to experience recurrence. This was not observed in a prior study of LLD (Hinrichsen & Hernandez 1993) , and conclusions are mixed in midlife depression (Kuehner & Huffziger 2013; Mueller et al., 1999 ).
An earlier age of initial depressive episode is also a risk factor for recurrence, although past studies have not always observed this relationship (Burcusa & Iacono 2007; Patten et al., 2010; Stoudemire, 1997) . Importantly, in a secondary model with a slightly reduced sample, neither age of onset nor sex was associated with recurrence after including a dichotomous variable of reporting more than three prior depressive episodes. Thus, earlier age of onset and female sex may be the characteristics of a highly recurrent depression phenotype.
Past studies inconsistently report relationships between environmental stressors and recurrence. In our final parsimonious model, perceived stress severity but not quantitative measures of stressful events predicted recurrence. This suggests that stressful events themselves may be less relevant to recurrence than one's subjective response.
Higher levels of social support could potentially mitigate the effect of stress; however, recurrence risk was reduced only by higher levels of instrumental social support, or social assistance with activities. This social support measure may be particularly associated with greater disability. This is an important consideration as we excluded individuals with severe physical disabilities that interfered with cognitive testing.
The combination of greater disability and less assistance with activities may be a particularly problematic combination.
Effects of depressive symptomatology
Our association of recurrence with greater residual depressive symptoms measured during the precensoring assessment is concordant with past reports that residual symptoms increase risk of recurrence.
However, the mean group difference of two points in precensoring MADRS score may be challenging to distinguish and interpret clinically.
Thus, symptom severity monitoring alone may not clearly inform who needs clinical intervention.
Two specific depressive symptoms also predicted recurrence. One item, measured by self-report on the CES-D, is the frequency of sad feelings, a finding not observed for the comparable physician-assessed MADRS item. This discrepancy may be related to the structure of the MADRS item that incorporates sadness intensity and does not purely focus on frequency. It could also be related to differences in reporting bias between physician-and self-report measures, as subject responses may be influenced by the relationship with their physicians. This symptom may reflect a persistently decreased ability to selfregulate mood. The discrepancy between CES-D and MADRS items raises concerns for Type 1 errors; however, this concern is mitigated by our focus on the final statistical models. The second symptom was the presence of thoughts of death measured by MADRS. This is particularly important as not all subjects develop thoughts of death or suicidality, while suicidality is associated with distinct neurobiological findings (Desmyter, van Heeringen, & Audenaert, 2011; Taylor et al., 2015) . However, this item was no longer associated with recurrence after adjusting for reporting more than three prior episodes, supporting that suicidality may be more common in highly recurrent depression. Neuropsychological test models examine z-transformed cognitive domain scores, controlling for age, sex, and education. Neuroimaging measures are presented in milliliters and models control for age, sex, and total cerebral volume, except for models focusing solely on total cerebral volume that control only for age and sex. Sample size included for each model due to missing data. MMSE, Mini-mental state exam.
TA B L E 3 Neuropsychological and neuroimaging factors' effects on recurrence
Important negative findings
There are several important negative findings. Although continuation treatment reduces risk of relapse or recurrence (Gueorguieva et al., 2017; Reynolds et al., 2006) , our study did not associate cessation of antidepressant medications with recurrence. However, over 90% of the study subjects were taking antidepressants at censoring, so this analysis may have been underpowered to detect an effect in the small number of participants who stopped antidepressant medications. In contrast, anxiolytic use was associated with increased recurrence risk in initial models, but not the final parsimonious model. Anxiolytic use may be a marker of residual anxiety as more severe anxiety symptoms in LLD are associated with recurrence (Andreescu et al., 2007) . Unfortunately, we did not have a measure of anxiety severity, only a dichotomous diagnosis of GAD at entry.
Measures of neuropsychological performance and brain aging were also unrelated to recurrence risk. This is consistent with prior work in LLD examining the relationship between recurrence risk and executive dysfunction (Butters et al., 2004) , but not reports in nongeriatric adult depression associating memory impairment with recurrence risk (Maeshima et al., 2016) . This difference may be related to timing of the neuropsychological testing: our testing occurred during an active depressive episode, while others measured performance at remission (Maeshima et al., 2016) . As cognitive performance can improve with antidepressant treatment (Barch et al., 2012) , our findings may differ had the battery been administered at remission. Similarly, we did not observe a relationship between imaging measures of brain aging and recurrence. However, only a subsample of participants had MRI data, decreasing our power to identify relationships with recurrence risk. Moreover, our past work has reported that cross-sectional assessments may be less related to long-term outcomes than longitudinal measures of change (Taylor et al., 2003 . These negative imaging and neuropsychological findings are concordant with our observation that earlier age of depression onset is associated with greater recurrence risk, as individuals with earlier ages of onset often have less severe age-related brain changes (Herrmann, Le Masurier, & Ebmeier, 2008) . Perhaps other factors contributing to EOD, such as sex, genetics, and early adversity may be more relevant for recurrence than brain aging and cognitive decline.
Strengths and limitations
To our knowledge, this is the largest study of recurrence in a clinical LLD sample. It has several strengths, including the duration of 
Implications and future directions
In conclusion, specific demographics, environmental factors, and depressive symptoms predict recurrence in late life. These data provide a starting point for clinicians and patients in a shared decisionmaking process about ongoing treatment and recurrence risks after remission and suggests possible targets for interventions aimed at maintaining remission. This work will inform future research aimed at developing personalized risk stratification algorithms that may be applied clinically. Further directions also include exploring how differences in cognition and brain function that persist with remission may be related to recurrence.
